Skip to main content
Top
Published in:

Open Access 01-12-2024 | Endometrial Cancer | Analysis

Identification of genetic and immune mechanisms linking preeclampsia and endometrial cancer: a prognostic model for survival and treatment response

Authors: Fei Teng, Guangjuan Fang, Jing Wang, Yongxiu Yang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Preeclampsia (PE) and endometrial cancer (EC) are two distinct conditions that share common genetic and molecular mechanisms involving immune dysregulation, endothelial dysfunction, and angiogenesis. This study aimed to investigate the potential genetic links between PE and EC, identify key prognostic genes, and develop a risk model to predict overall survival in EC patients. We conducted comprehensive genetic and molecular analyses, revealing significant overlaps in immune and angiogenic pathways between PE and EC. Through LASSO regression and multivariate Cox analysis, we identified five core prognostic genes—FSTL3, PRSS23, IGFBP4, MYDGF, and TSC22D3—that were used to construct a risk model. This model effectively stratified EC patients into high- and low-risk groups, with significant differences in overall survival. Patients in the low-risk group exhibited better 1-, 3-, and 5-year survival outcomes and had higher immune cell infiltration and expression of immune checkpoint-related genes, indicating a more favorable tumor microenvironment. Additionally, the analysis showed that these genes are also implicated in the pathogenesis of PE, highlighting potential shared molecular mechanisms. Our findings suggest that these PE-related genes may serve as valuable prognostic biomarkers for EC and could lead to improved prognostic tools and personalized treatment strategies for EC patients.
Literature
1.
go back to reference Dymara-Konopka W, Laskowska M, Oleszczuk J. Preeclampsia—current management and future approach. Curr Pharm Biotechnol. 2018;19(10):786–96.CrossRefPubMed Dymara-Konopka W, Laskowska M, Oleszczuk J. Preeclampsia—current management and future approach. Curr Pharm Biotechnol. 2018;19(10):786–96.CrossRefPubMed
2.
go back to reference Nirupama R, et al. Preeclampsia: pathophysiology and management. J Gynecol Obstet Hum Reprod. 2021;50(2): 101975.CrossRefPubMed Nirupama R, et al. Preeclampsia: pathophysiology and management. J Gynecol Obstet Hum Reprod. 2021;50(2): 101975.CrossRefPubMed
3.
go back to reference Roberts JM. Preeclampsia epidemiology(ies) and pathophysiology(ies). Best Pract Res Clin Obstet Gynaecol. 2024;94: 102480.CrossRefPubMed Roberts JM. Preeclampsia epidemiology(ies) and pathophysiology(ies). Best Pract Res Clin Obstet Gynaecol. 2024;94: 102480.CrossRefPubMed
5.
go back to reference Chaemsaithong P, et al. Pharmacogenomics of preeclampsia therapies: current evidence and future challenges for clinical implementation. Best Pract Res Clin Obstet Gynaecol. 2024;92: 102437.CrossRefPubMed Chaemsaithong P, et al. Pharmacogenomics of preeclampsia therapies: current evidence and future challenges for clinical implementation. Best Pract Res Clin Obstet Gynaecol. 2024;92: 102437.CrossRefPubMed
6.
go back to reference Arend RC, et al. EC: Molecular markers and management of advanced stage disease. Gynecol Oncol. 2018;150(3):569–80.CrossRefPubMed Arend RC, et al. EC: Molecular markers and management of advanced stage disease. Gynecol Oncol. 2018;150(3):569–80.CrossRefPubMed
7.
go back to reference Kim H, Kim HJ, Ahn HS. Does endometriosis increase the risks of endometrial hyperplasia and EC? Gynecol Oncol. 2023;169:147–53.CrossRefPubMed Kim H, Kim HJ, Ahn HS. Does endometriosis increase the risks of endometrial hyperplasia and EC? Gynecol Oncol. 2023;169:147–53.CrossRefPubMed
9.
go back to reference Cai Y, et al. EC: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem. 2021;28(42):8755–81.CrossRefPubMed Cai Y, et al. EC: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem. 2021;28(42):8755–81.CrossRefPubMed
11.
go back to reference Marín-Jiménez JA, et al. Facts and hopes in immunotherapy of EC. Clin Cancer Res. 2022;28(22):4849–60.CrossRefPubMed Marín-Jiménez JA, et al. Facts and hopes in immunotherapy of EC. Clin Cancer Res. 2022;28(22):4849–60.CrossRefPubMed
14.
go back to reference Liu Y, et al. Complications of pregnancy and the risk of developing endometrial or ovarian cancer: a case-control study. Front Endocrinol (Lausanne). 2021;12: 642928.CrossRefPubMed Liu Y, et al. Complications of pregnancy and the risk of developing endometrial or ovarian cancer: a case-control study. Front Endocrinol (Lausanne). 2021;12: 642928.CrossRefPubMed
15.
go back to reference Bokuda K, Ichihara A. Preeclampsia up to date—what’s going on? Hypertens Res. 2023;46(8):1900–7.CrossRefPubMed Bokuda K, Ichihara A. Preeclampsia up to date—what’s going on? Hypertens Res. 2023;46(8):1900–7.CrossRefPubMed
16.
go back to reference Rios DRA, et al. Increased levels of sENG and sVCAM-1 and decreased levels of VEGF in severe preeclampsia. Am J Hypertens. 2016;29(11):1307–10.CrossRefPubMed Rios DRA, et al. Increased levels of sENG and sVCAM-1 and decreased levels of VEGF in severe preeclampsia. Am J Hypertens. 2016;29(11):1307–10.CrossRefPubMed
17.
go back to reference Zhang L, et al. The diagnosis values of serum STAT4 and sEng in preeclampsia. J Clin Lab Anal. 2020;34(2): e23073.CrossRefPubMed Zhang L, et al. The diagnosis values of serum STAT4 and sEng in preeclampsia. J Clin Lab Anal. 2020;34(2): e23073.CrossRefPubMed
18.
go back to reference Azadehrah M, Vosoogh S, Azadehrah M. The roles and therapeutic applications of cytokines in EC. J Reprod Immunol. 2022;152: 103652.CrossRefPubMed Azadehrah M, Vosoogh S, Azadehrah M. The roles and therapeutic applications of cytokines in EC. J Reprod Immunol. 2022;152: 103652.CrossRefPubMed
20.
go back to reference Yang FF, et al. Small molecule targeted therapies for EC: progress, challenges, and opportunities. RSC Med Chem. 2024;15(6):1828–48.CrossRefPubMed Yang FF, et al. Small molecule targeted therapies for EC: progress, challenges, and opportunities. RSC Med Chem. 2024;15(6):1828–48.CrossRefPubMed
23.
go back to reference Dey DK, et al. The role and participation of immune cells in the endometrial tumor microenvironment. Pharmacol Ther. 2023;251: 108526.CrossRefPubMed Dey DK, et al. The role and participation of immune cells in the endometrial tumor microenvironment. Pharmacol Ther. 2023;251: 108526.CrossRefPubMed
24.
go back to reference Aisagbonhi O, et al. High placental expression of FLT1, LEP, PHYHIP and IL3RA—in persons of African ancestry with severe preeclampsia. Placenta. 2023;144:13–22.CrossRefPubMedPubMedCentral Aisagbonhi O, et al. High placental expression of FLT1, LEP, PHYHIP and IL3RA—in persons of African ancestry with severe preeclampsia. Placenta. 2023;144:13–22.CrossRefPubMedPubMedCentral
25.
26.
go back to reference Oehler MK, Brand A, Wain GV. Molecular genetics and EC. J Br Menopause Soc. 2003;9(1):27–31.PubMed Oehler MK, Brand A, Wain GV. Molecular genetics and EC. J Br Menopause Soc. 2003;9(1):27–31.PubMed
27.
28.
go back to reference Trabert B, et al. Associations of pregnancy-related factors and birth characteristics with risk of EC: a Nordic population-based case-control study. Int J Cancer. 2020;146(6):1523–31.CrossRefPubMed Trabert B, et al. Associations of pregnancy-related factors and birth characteristics with risk of EC: a Nordic population-based case-control study. Int J Cancer. 2020;146(6):1523–31.CrossRefPubMed
29.
go back to reference Kostakis ID, et al. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol. 2010;151(1):3–9.CrossRefPubMed Kostakis ID, et al. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol. 2010;151(1):3–9.CrossRefPubMed
30.
go back to reference Aarnio M, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.CrossRefPubMed Aarnio M, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.CrossRefPubMed
31.
go back to reference Li X, et al. FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation. Obesity (Silver Spring). 2023;31(1):171–83.CrossRefPubMed Li X, et al. FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation. Obesity (Silver Spring). 2023;31(1):171–83.CrossRefPubMed
33.
go back to reference Shi Y, et al. AKAP12 and IGFBP4 are prognostic factors for chronic lymphocytic leukemia. Acta Haematol. 2023;146(6):474–81.CrossRefPubMed Shi Y, et al. AKAP12 and IGFBP4 are prognostic factors for chronic lymphocytic leukemia. Acta Haematol. 2023;146(6):474–81.CrossRefPubMed
Metadata
Title
Identification of genetic and immune mechanisms linking preeclampsia and endometrial cancer: a prognostic model for survival and treatment response
Authors
Fei Teng
Guangjuan Fang
Jing Wang
Yongxiu Yang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-01622-9

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more